Step down to 6 months of prophylactic-dose low molecular weight heparin after initial full-dose anticoagulation for the treatment of cancer-associated thrombosis (STEP-CAT): A pilot study
- PMID: 35587536
- DOI: 10.1111/jth.15760
Step down to 6 months of prophylactic-dose low molecular weight heparin after initial full-dose anticoagulation for the treatment of cancer-associated thrombosis (STEP-CAT): A pilot study
Abstract
Background: Patients with cancer-associated thrombosis (CAT) are treated with full-dose anticoagulation for at least 3 months, but optimal dosing thereafter is unknown.
Aim: We explored the feasibility of extended prophylactic-dose low molecular weight heparin (LMWH) treatment following a minimum of 3 months of full-dose LMWH.
Methods: We conducted a multicenter prospective pilot study of patients with CAT who completed at least 3 months of therapeutic-dose LMWH. Patients received 6 months of prophylactic-dose subcutaneous enoxaparin (40 mg once daily). The primary outcome was recurrence of deep vein thrombosis (DVT) or pulmonary embolism (PE), and secondary outcomes included major, clinically relevant non-major (CRNM), and minor bleeding.
Results: From August 2016 to May 2019, 52 patients with a mean age of 64.1 years were included. The study was stopped early because of poor recruitment. Breast (23.1%) and colorectal (19.2%) were the most common cancers, and 61.0% had stage IV malignancy. Index CAT consisted of DVT alone in 57.7% of patients and pulmonary embolism (PE) with or without DVT in 42.3%. Patients received a mean of 7.6 months of weight-adjusted LMWH before enrollment. During a mean follow-up of 5.6 months, one patient was diagnosed with recurrent incidental PE (0.0035 events/subject-month). There were no major bleeding events, one CRNM, and one minor bleeding event. Eight (15.4%) patients died; six from cancer and two from respiratory disease unrelated to PE.
Conclusions: These results, in part, provide support for trials of extended reduced-dose anticoagulation for the secondary prevention of CAT. (ClinicalTrials.gov: NCT02752607).
Keywords: anticoagulants; heparin, low-molecular-weight; neoplasms; pulmonary embolism; venous thrombosis.
© 2022 International Society on Thrombosis and Haemostasis.
Similar articles
-
Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study.Oncol Res Treat. 2022;45(4):178-185. doi: 10.1159/000521698. Epub 2021 Dec 28. Oncol Res Treat. 2022. PMID: 34963120
-
A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).Health Technol Assess. 2015 Oct;19(83):vii-xxiii, 1-93. doi: 10.3310/hta19830. Health Technol Assess. 2015. PMID: 26490434 Free PMC article. Clinical Trial.
-
Interventions for preventing venous thromboembolism in adults undergoing knee arthroscopy.Cochrane Database Syst Rev. 2020 May 6;5(5):CD005259. doi: 10.1002/14651858.CD005259.pub4. Cochrane Database Syst Rev. 2020. Update in: Cochrane Database Syst Rev. 2022 Aug 22;8:CD005259. doi: 10.1002/14651858.CD005259.pub5. PMID: 32374919 Free PMC article. Updated.
-
Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.Thromb Haemost. 2002 Dec;88(6):938-42. Thromb Haemost. 2002. PMID: 12529742
-
What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?Thromb Res. 2007;119(3):265-74. doi: 10.1016/j.thromres.2006.03.010. Epub 2006 May 3. Thromb Res. 2007. PMID: 16674999 Review.
Cited by
-
Prediction model of gastrointestinal tumor malignancy based on coagulation indicators such as TEG and neural networks.Front Immunol. 2025 Mar 25;16:1507773. doi: 10.3389/fimmu.2025.1507773. eCollection 2025. Front Immunol. 2025. PMID: 40201179 Free PMC article.
References
REFERENCES
-
- Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012;9:e1001275.
-
- Brose KM, Lee AY. Cancer-associated thrombosis: prevention and treatment. CurrOncol. 2008;15:S58-S67.
-
- Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost. 2011;9(Suppl 1):316-324.
-
- Tagalakis V, Wharin C, Kahn SR. Comprehensive update on the prevention and treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost. 2013;39:127-140.
-
- Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;100:3484-3488.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous